Cerebral oxygen saturation as outcome predictor after transfemoral transcatheater aortic valve implantation

Philipp C. Seppelt1,2 · Silvia Mas-Peiro1,2 · Arnaud Van Linden2,3 · Sonja Iken4 · Kai Zacharowski4 · Thomas Walther2,3 · Stephan Fichtlscherer1,2 · Mariuca Vasa-Nicotera1,2

Received: 12 December 2021 / Accepted: 31 March 2022 / Published online: 4 May 2022
© The Author(s) 2022

Abstract

Background  Cerebral oxygen saturation (ScO2) can be measured non-invasively by near-infrared spectroscopy (NIRS) and correlates with cerebral perfusion. We investigated cerebral saturation during transfemoral transcatheater aortic valve implantation (TAVI) and its impact on outcome.

Methods and results  Cerebral oxygenation was measured continuously by NIRS in 173 analgo-sedated patients during transfemoral TAVI (female 47%, mean age 81 years) with self-expanding (39%) and balloon-expanding valves (61%). We investigated the periprocedural dynamics of cerebral oxygenation. Mean ScO2 at baseline without oxygen supply was 60%. During rapid ventricular pacing, ScO2 dropped significantly (before 64% vs. after 55%, p < 0.001). ScO2 at baseline correlated positively with baseline left-ventricular ejection fraction (0.230, p < 0.006) and hemoglobin (0.327, p < 0.001), and inversely with EuroSCORE-II (−0.285, p < 0.001) and length of in-hospital stay (−0.229, p < 0.01). Patients with ScO2 < 56% despite oxygen supply at baseline had impaired 1 year survival (log-rank test p < 0.01) and prolonged in-hospital stay (p = 0.03).

Furthermore, baseline ScO2 was found to be a predictor for 1 year survival independent of age and sex (multivariable adjusted Cox regression, p = 0.020, hazard ratio (HR 0.94, 95% CI 0.90–0.99) and independent of overall perioperative risk estimated by EuroSCORE-II and hemoglobin (p = 0.03, HR 0.95, 95% CI 0.91–0.99).

Conclusions  Low baseline ScO2 not responding to oxygen supply might act as a surrogate for impaired cardiopulmonary function and is associated with worse 1 year survival and prolonged in-hospital stay after transfemoral TAVI. ScO2 monitoring is an easy to implement diagnostic tool to screen patients at risk with a potential preserved recovery and worse outcome after TAVI.

Graphical abstract

Cerebral oxygen saturation (ScO2) in a TAVI cohort

- mean age 81 years (47% female)
- measured by near-infrared spectroscopy (NIRS)
- mean ScO2 at baseline w/o oxygen supply: 60%

ScO2 correlates with

- hemoglobin
- length of in-hospital stay
- LVEF

Impaired outcome in patients with low ScO2 at baseline (<56%)

Extended author information available on the last page of the article
Keywords  Valvular cardiomyopathy · Aortic stenosis · Cerebral oxygen saturation · TAVI

Abbreviations
CAM-ICU  Confusion Assessment Method for the ICU
EuroSCORE-II  European System for Cardiac Operative Risk Evaluation Score II
Hb  Serum hemoglobin concentration
LVEF  Left-ventricular ejection fraction
MMSE  Mini-Mental State examination
NIRS  Near-infrared spectroscopy
NT-proBNP  N-terminal pro-brain natriuretic peptide
RVP  Rapid ventricular pacing
ScO2  Cerebral oxygen saturation
SpO2  Peripheral oxygen saturation
SVI  Stroke volume index–stroke volume/body surface area
TAVI  Transcatheter aortic valve implantation

Introduction
TAVI has become the gold standard for treatment of degenerative aortic valve stenosis in older patients with high-to-intermediate operative risks [1]. Predictors for favorable long-term survival and quality of life after TAVI are of high interest, since a relevant proportion of TAVI patients have cerebral and neurocognitive comorbidities. In a previous pilot study, we described the correlation between decline of cerebral oxygenation during rapid ventricular pacing for TAVI and postoperative delirium [2]. Real-time measured cerebral O2 saturation reflects cerebral perfusion and mirrors the central venous oxygen saturation, one important determinant of the systemic oxygen balance [3, 4]. Cerebral oxygen saturation can be measured non-invasively and continuously by near-infrared spectroscopy (NIRS). Methodically, NIRS measures the relative changes of the different light absorption spectra of oxygenated and deoxygenated hemoglobin. NIRS configurations used in clinical practice with sensor pads placed at the forehead determine cerebral blood saturation in a ratio of about 84% venous and 16% arterial blood [5]. One important methodological limitation of NIRS for ScO2 measurement is the inability to detect hypoperfusions outside of the frontal cerebral lobes. NIRS for cerebral oxygenation saturation measurement has been widely studied in different clinical settings including surgery, resuscitation and cerebral injury [6–9]. The role of cerebral oxygen saturation and its impact on outcome parameters has not yet been investigated in the setting of TAVI. In this study, we analyzed the association of intraprocedural measured cerebral oxygenation with baseline and outcome parameters in patients with aortic valve stenosis undergoing transfemoral TAVI.

Methods

Study design
Between July 2018 and December 2020, we measured ScO2 in 173 patients receiving transfemoral TAVI in analgo-sedation. All patients underwent preoperative duplex sonography of the supra-aortic vessels, echocardiography (transthoracic or transesophageal) and computed tomography for procedure planning and valve sizing. Low-flow low-gradient aortic stenosis with reduced ejection fraction was defined according to guideline recommendations: aortic valve area (AVA)<1.0 cm2, mean transvalvular pressure < 40 mmHg, left-ventricular ejection fraction (LVEF)<50% and stroke volume index < 35 ml/m2 (SVI) [10]. Carotid artery disease was defined as at least 10% stenosis according to the NASCET-Classification [11]. NASCET stenosis of > 50%, indicating moderate-to-severe carotid artery disease, were evaluated separately. Patients with symptomatic carotid artery disease or indication for revascularization were not included. Performance in activities of daily living was determined by Barthel-Index and cognitive impairment by MMSE (Mini-Mental State examination) [12]. An MMSE result below 24 points was interpreted as abnormal indicating a cognitive impairment [13]. An invasive dual-pressure analysis was performed to obtain aortic valve gradients and left-ventricular end-diastolic pressure before the first rapid ventricular pacing or valve implantation and at the end of the procedure. Postoperative delirium was assessed and diagnosed by CAM-ICU (Confusion Assessment Method for the intensive care unit) during the first 2 postoperative days or later if delirium was suspected [14]. Decision for valve intervention, selection of approach, and valve type were made by an interdisciplinary heart team consisting of cardiologists, cardiac surgeons, and anesthesiologists and further disciplines when needed. Patients in cardiogenic shock or patients requiring inotropic support prior to the procedure were excluded from analysis. Before discharge valve prosthesis function was assessed by transthoracic echocardiography. Outcome parameters were reported according to the VARC-3 criteria [15]. The study and data collection were approved by the ethics committee of the University Hospital of Frankfurt (296/16 and 19/461), and all patients gave signed and informed consent prior to intervention. Long-term follow-up information was obtained via contact with general practitioners, other hospitals, or with the patient or family directly.
Transcatheter aortic valve implantation

TAVI procedures were performed in our hybrid operating room in Heart Team approach by an interventional cardiologist, a cardiac surgeon and a cardiac anesthesiologist. Procedures were performed exclusively under analgo-sedation using fentanyl (1–2 μg/kg body weight). One patient received remifentanil and 5 patients received midazolam additionally (intravenous 1–2 mg). Mepicavain was infiltrated at the puncture sites for local anesthesia (10–20 ml 10 mg/ml). Femoral access was obtained with re-closure devices (either Perclose ProGlide, Abbott Vascular, Abbott Park, Illinois, USA or Manta closure device, Teleflex, Pennsylvania, USA). For rapid ventricular pacing (RVP) a temporary pacing wire was placed via the femoral vein in the right ventricular apex. Retrograde passing of the aortic stenosis was performed as per interventionist standard. Before changing to a stiff pre-shaped wire for valve deployment (SAFARI2 Boston Scientific, Massachusetts, USA), dual-invasive pressure analysis was performed with two pigtail catheters in the aorta and left ventricle. If required, RVP was performed for pre-dilatation, for valve deployment and for prosthesis post-dilatation. Prosthesis function was evaluated by aortic angiogram and invasive dual catheter pressure analysis. At the end of the procedure, patients were transferred to an intermediate care unit and were monitored for at least 48 h post-intervention.

Measurements of cerebral oxygenation

Regional cerebral oxygenation (ScO₂) was monitored by placing two NIRS optodes on the forehead (Root®, Masimo, Irvine, USA). Values for both hemispheres were documented, but the mean value was used for analysis. The baseline values were determined before induction of analgo-sedation without oxygen supply (Fig. 1). Only if the peripheral oxygen saturation (SpO₂, measured by standard peripheral oximetry) was below 95%, patients received supplementary oxygen. The ScO₂ values were recorded continuously and values prior, during and 5 min after last RVP or valve deployment were documented. If two or more RVPs were performed mean values were used for analysis. Additionally, the lowest and highest intraprocedural ScO₂ were documented.

Statistics

Continuous variables are shown as mean ± standard deviation and categorical data are shown as number (percentage). European System for Cardiac Operative Risk Evaluation Score II (EuroSCORE-II) and Barthel-Index are presented as median ± interquartile range [16]. Unadjusted differences were compared with $\chi^2$ tests for categorical variables and 2-tailed unpaired Student’s t tests for continuous variables. Mann–Whitney U Test was applied for non-parametric testing or for sample sizes < 50. Because of its robustness, non-parametric Spearman’s Rho test was used to measure the strength of association between intraprocedural ScO₂ and baseline/outcome variables. We determined the predictive value of intraprocedural measured ScO₂ for 1 year survival by receiver-operating characteristic curve (ROC) analysis. Perfect cut-off values were calculated using Youden index with priority on optimizing sensitivity to screen for true-positive cases (patients at risk) [17]. Long-term survival was estimated by Kaplan–Meier function and distinctions between subgroups were verified by log-rank test. Furthermore 1 year survival was analyzed by Cox proportional hazards regression model adjusted to baseline variables. In model 1, age, sex and hemoglobin at baseline, and in model 2, EuroSCORE-II and hemoglobin at baseline were included into the model as fixed variables. Model 3 contained low-flow low-gradient aortic stenosis and the type

Protocol for cerebral oxygen saturation analysis during TAVI

Fig. 1 Protocol for cerebral oxygen saturation (ScO₂) measurement during transfemoral TAVI procedure. ScO₂ cerebral oxygen saturation, SpO₂ peripheral oxygen saturation, TAVI transcatheter aortic valve implantation
of valve prothesis as fixed variables (balloon-expandable or self-expandable valve). Intraprocedural ScO2 values were tested with both models en bloc in a single step (Enter mode). The a priori level of statistical significance was set at \( p < 0.05 \) for all analyses, which were always 2-tailed and performed with SPSS, MedCalc and R (IBM SPSS 25, Chicago, USA, MedCalc Software Ltd, Ostend, Belgium and R 3.6.1, www.r-project.org).

Results

Baseline characterization

The mean age in our study cohort was 81 years (47.4% female) with a median perioperative risk of 4.1% according to EuroSCORE-II (intermediate risk, Table 1). A median Barthel-Index of 90 points indicates only minor limitations in activities of daily living for most patients (19.5% of the patients < 75 points). At least mild-to-moderate carotid artery disease was present in 50 patients (28.9%) and moderate-to-severe carotid artery disease in 15 patients (8.7%). Twenty patients had a cerebral bleeding or a minor or major stroke in their medical history (11.6%). Nine patients suffered from pre-existing dementia (5.2%) and 48 patients (27.7%) had mild-to-moderate impaired cognitive function according to MMSE. Transthoracic echocardiography revealed mean baseline left-ventricular ejection fraction of 53% (Table 2). All patients underwent TAVI for severe aortic stenosis (mean aortic valve area 0.82 cm\(^2\)) and were classified either as normal-flow high-gradient (\( n = 102, 59.3\% \)) or as low-flow low-gradient (\( n = 32, 18.5\% \)) aortic stenosis with a mean gradient of 43.6 mmHg and 24.5 mmHg, respectively. Anemia defined as hemoglobin (Hb) at baseline < 12 g/dl in women and < 13 g/dl in men was found in 74% in women (mean hemoglobin, Hb 11.9 g/dl) and 55% in men (mean Hb 12.4 g/dl).

TAVI procedure

In 105 patients (60.7%) a self-expandable and in 68 patients (39.3%) a balloon-expandable prothesis was implanted (Table 3). In 29 implantations, no RVP (16.8%) and in 98 implantations one RVP was conducted (56.6%; two or more RVP, in \( n = 46, 26.6\% \)).

Intraprocedural measurement of regional cerebral oxygenation by NIRS

Mean baseline ScO2 was 60.4% and increased after oxygen supply (63.9%, \( p < 0.001 \); Fig. 2), but did not differ between cerebral hemispheres (left 60.3% vs. 60.5% right, \( p = 0.745 \)). All patients were analgo-sedated, spontaneously breathing and 95.4% of the patients received oxygen supply (mean 5.3 l/min, aimed peripheral oxygen saturation > 95%).

Table 1
Patient characteristics (\( n = 173 \))

| Characteristic                      | Value               |
|-------------------------------------|---------------------|
| Female                              | 82 (47.4%)          |
| Age (years)                         | 81.0 ± 6.0          |
| Body mass index (kg/m\(^2\))        | 27.1 ± 5.8          |
| EuroSCORE-II (%)\(^a\)              | 4.1 (2.2–6.8)       |
| Barthel-Index (0–100 points)\(^a\)  | 90 (80–90)          |
| NYHA III                            | 121 (69.9%)         |
| NYHA IV                             | 15 (8.7%)           |
| Hemodialysis (n)                    | 5 (2.9%)            |
| Previous cardiac decompensation (n) | 79 (45.7%)          |
| Diabetes mellitus (n)               | 62 (35.8%)          |
| Atrial fibrillation (n)             | 58 (33.5%)          |
| Permanent pacemaker (prior to TAVI, n) | 18 (10.4%)        |
| Coronary heart disease (n)          | 102 (59%)           |
| Previous PCI (n)                    | 70 (40.7%)          |
| Previous myocardial infarction (n)  | 33 (19.1%)          |
| Cerebral arterial disease (n)       | 50 (28.9%)          |
| Mild-to-moderate                    | 35 (20.2%)          |
| Moderate-to-severe                  | 15 (8.7%)           |
| Stroke (n, minor or major)          | 20 (11.6%)          |
| Dementia (n)                        | 9 (5.2%)            |
| Cognitive impairment (MMSE < 24 points, n) | 48 (27.7%)         |
| Peripheral artery disease (n)       | 59 (34.1%)          |
| Chronic lung disease (n)            | 47 (27.1%)          |
| Hemoglobin (g/dl)                   | 12.1 ± 1.9          |
| Creatinine (mg/dl)                  | 1.29 ± 0.9          |
| NT-proBNP (ng/l)                    | 4776 ± 13,021       |
| High-sensitive Troponin-T (ng/l)    | 52 ± 110            |

Data shown as n (percentage) or mean (± standard deviation)

\(^a\)EuroSCORE-II and Barthel-Index are presented as median (interquartile range)

Table 2
Baseline echocardiography

| Characteristic                        | Value            |
|---------------------------------------|------------------|
| LVEF (%)                              | 53.0 ± 12.0      |
| Aortic valve area (cm\(^2\))          | 0.82 ± 0.27      |
| Mean aortic valve gradient (mmHg)     | 40 ± 16          |
| Maximum aortic valve gradient (mmHg)  | 62 ± 24          |
| Severe aortic valve insufficiency (n) | 9 (5.3%)         |
| Severe mitral valve insufficiency (n) | 20 (11.6%)       |
| Severe tricuspid valve insufficiency (n) | 14 (8.1%)       |
| Low-flow low-gradient aortic valve stenosis | 32 (18.5%)   |
| TAPSE (mm)                            | 21 ± 6           |
| Systolic pulmonary artery pressure (mmHg) | 41 ± 14         |

Data shown as n (percentage) or mean (± standard deviation)

\(^a\)LVEF left-ventricular ejection function, TAPSE tricuspid annular plane systolic excursion
During RVP for balloon dilatation or valve implantation, ScO2 declined significantly (63.9% vs. 55.2%, \( p < 0.001 \)) and raised to normalized values 5 min after RVP or valve implantation (55.2% vs. 63.6%, \( p < 0.001 \)). In cases with at least one RPV, baseline ScO2 did not differ, but ScO2 nadir was lower compared to cases without RVP (52.0% vs. 55.1%, \( p = 0.03 \)).

### Correlation of cerebral oxygen saturation with baseline characteristics

Baseline ScO2 correlated inversely with estimated perioperative risk (EuroSCORE-II, −0.285, \( p < 0.001 \)) and with the cardiac biomarkers NT-proBNP (N-terminal pro-brain natriuretic peptide, −0.334, \( p < 0.001 \)) and high-sensitive Troponin-T (−0.256, \( p < 0.001 \)). Furthermore, Hb concentration correlated significantly with baseline ScO2 (0.327, \( p < 0.001 \)) and patient with baseline ScO2 below the median (<60.5%) had significant lower Hb concentration (11.6 vs. 12.6 g/dl, \( p < 0.001 \)). LVEF was found to correlate with ScO2 at baseline (0.230, \( p < 0.01 \), lowest measured ScO2 (0.312, \( p < 0.001 \)) and delta highest-lowest ScO2 (−0.359, \( p < 0.001 \)). Patients with low-flow low-gradient aortic valve stenosis had lower ScO2 at baseline without (57.0 vs. 61.2%, \( p < 0.001 \)) and with oxygen supply (60.8 vs. 64.7%, \( p < 0.01 \)), during RVP (51.2 vs. 56.1%, \( p < 0.01 \)) and lowest documented ScO2 (49 vs. 53.6%, \( p < 0.01 \)). In the entire cohort, lower baseline and lowest intraprocedural ScO2 were inversely associated with longer in-hospital stay (−0.229, \( p < 0.01 \) and −0.185, \( p = 0.015 \) respectively) and delta highest–lowest ScO2 correlated with the development of postoperative delirium (0.286, \( p < 0.001 \)). If a decline in ScO2 of >20% occurred during the procedure, patients suffered more often from postoperative delirium (34.0% vs. 15.8%, \( p < 0.01 \)). Patients with baseline ScO2 below 56% stayed

### Table 3 Procédural outcome (\( n = 173 \)) according to VARC-3 [15]

| Data shown as \( n \) (percentage) or mean ± standard deviation |
|---|
| RVP rapid ventricular pacing |
| Aortic valve prostheses |
| Edwards S3/S3 Ultra \( n \) | 68 (39.3%) |
| Boston scientific ACURATE neo \( n \) | 59 (34.1%) |
| St. Jude Portico \( n \) | 23 (13.3%) |
| Medtronic evolute Pro/R \( n \) | 23 (13.3%) |
| Valve in valve procedure \( n \) | 4 (2.3%) |
| Valve size (mm) | 26.63 ± 2.6 |
| RVP \( n \) of the patients \( n = 0 \) | 29 (16.8%) |
| RVP \( n \) of the patients \( n = 1 \) | 98 (56.6%) |
| RVP \( n \) of the patients \( n = 2 \) | 41 (23.7%) |
| RVP \( n \) of the patients \( n = 3 \) | 4 (2.3%) |
| RVP \( n \) of the patients \( n = 4 \) | 1 (0.6%) |
| Balloon pre-dilatation \( n \) of the cases | 91 (52.6%) |
| Balloon post-dilatation \( n \) of the cases | 35 (20.2%) |
| Contrast medium (ml) | 85.7 ± 49.0 |
| Fluoroscopy time (min) | 13.2 ± 9.0 |
| Postoperative \( n \) | 45 (26.0%) |
| Serious access site vascular complication \( n \) | 5 (2.9%) |
| Severe prosthetic aortic valve regurgitation \( n \) | 1 (0.6%) |
| Mean aortic valve gradient (mmHg) | 9.5 ± 6.2 |
| Maximum aortic valve gradient (mmHg) | 17.3 ± 9.5 |
| Stroke \( n \) | 4 (2.3%) |
| Valve reoperation \( n \) | 4 (2.3%) |
| Need for new pacemaker \( n \) | 33 (19.1%) |
| 30 day mortality \( n \) | 3 (1.7%) |
| Days on Intensive Care Unit (days) | 3.3 ± 2.3 |
| Days in hospital (days) | 8.9 ± 7.2 |

Fig. 2 Course of cerebral oxygen saturations during transfemoral TAVI. Mean ScO2 values measured at both frontal hemispheres at the different time points during TAVI procedure. ScO2 cerebral oxygen saturation, SpO2 peripheral oxygen saturation, RVP rapid ventricular pacing, TAVI transcatheter aortic valve implantation. *During RVP or valve deployment; **p < 0.001, Student’s \( t \) test, in comparison to the previous timepoint.
significantly longer in hospital (14.9 vs. 8.0 days, \( p = 0.030 \)). However, we found no association of \( \text{ScO}_2 \) with age, Barthel-Index, dementia or cognitive impairment. Furthermore, \( \text{ScO}_2 \) at baseline did not differ in patients with mild-to-moderate (60.4%) or moderate-to-severe (62%) compared to patients with no carotid artery disease (60.5%, \( p = 0.466 \) and \( p = 0.360 \), respectively). However, we observed a weak negative correlation of carotid artery disease with post-rapid pacing \( \text{ScO}_2 \) (correlation efficient \( -0.170, p = 0.024 \)).

**Survival analysis**

Mean follow-up was 400 days, and cumulative 1 year survival 82.9%. Completeness of follow-up was 100% after 30 days and 89.6% after 1 year. There was a tendency for an impaired survival of patients with low-flow low-gradient aortic stenosis after 1 year (log-rank test, \( p = 0.09 \)) and a significantly reduced survival over the complete follow-up (\( p = 0.023 \)). ROC analysis revealed baseline \( \text{ScO}_2 \) (with oxygen supply) as a predictor for 1 year survival (AUC 0.66, \( p < 0.01 \)) and \( \text{ScO}_2 \) of 56% was determined as optimized cut-off value to screen for patients with favorable 1 year survival (calculated by Youden Index, sensitivity 0.91/specificity 0.41). Survival analysis revealed a significantly reduced 1 year survival (87.9% vs. 66.4%, log-rank test \( p < 0.01 \); Fig. 3) and overall survival for patients with \( \text{ScO}_2 \) at baseline <56% with oxygen supply (\( p = 0.013 \)). These patients had higher EuroSCORE-II (3.9 vs. 7.3%, \( p < 0.001 \), but did not differ in age (80.9 vs. 81.3 years, \( p = 0.636 \)). An intraprocedural \( \text{ScO}_2 \) drop by more than 20% of the highest measured \( \text{ScO}_2 \) value was not associated with worse 1 year survival (81.5% vs. 82%, log-rank test \( p = 0.901 \)) or prolonged in-hospital stay (median 7.0 and 7.0 days, \( p = 0.329 \)). Instead, \( \text{ScO}_2 \) at baseline under oxygen supply was found to be a predictor for 1 year survival independent of age and sex (multivariable adjusted Cox regression, \( p = 0.020 \), hazard ration, HR 0.94, 95% CI 0.90–0.99) and independent of overall perioperative risk estimated by EuroSCORE-II and hemoglobin (\( p = 0.03 \), HR 0.95, 95% CI 0.91–0.99, Table 4). Intervention with balloon-expandable valve was a predictor for improved 1 year survival but estimated 1 year survival was not significantly better (log-rank test, \( p = 0.144 \), 80.6% vs 89.2%) and patients were younger (79.8 vs. 82.1, \( p < 0.01 \)).

**Discussion**

There is no sufficient experience with how to interpret cerebral oxygen saturation during TAVI procedure and how it can be used to improve risk stratification and outcome prognosis. We identified correlations between pre-existing risk factors mirroring cardiovascular functionality and \( \text{ScO}_2 \) at baseline. Furthermore, patients with oxygen supply and \( \text{ScO}_2 < 56\% \) at baseline had worse 1 year survival. To the best of our knowledge, this is the first study to report cerebral oxygen saturation during transfemoral TAVI systematically in a larger cohort.

With our study, we aimed to address two questions. First, does \( \text{ScO}_2 \) correlate with pre-existing risk factors in
Table 4: Cox regression for 1 year survival analysis

| Variable                        | p Value | HR (95% CI)     |
|---------------------------------|---------|-----------------|
| **Model 1**                     |         |                 |
| Age                             | 0.64    | 1.02 (0.95–1.08)|
| Sex (male)                      | 0.84    | 0.93 (0.44–1.95)|
| Hemoglobin                      | 0.04    | 0.80 (0.66–0.99)|
| Baseline ScO2 + O2-supply       | 0.020   | 0.94 (0.90–0.99)|

| **Model 2**                     |         |                 |
| EuroSCORE II                    | 0.323   | 1.02 (0.98–1.07)|
| Hemoglobin                      | 0.096   | 0.83 (0.67–1.03)|
| Baseline ScO2 + O2-supply       | 0.028   | 0.95 (0.91–0.99)|

| **Model 3**                     |         |                 |
| Low-flow low-gradient           | 0.457   | 1.40 (0.58–3.36)|
| Valve prothesis                 | 0.034   | 0.38 (0.16–0.93)|
| Baseline ScO2 + O2-supply       | <0.001  | 0.92 (0.87–0.97)|

Multivariable Cox regression for 1 year survival analysis
ScO2 regional cerebral oxygen saturation, CI confidence interval, HR hazard ratio

*Variables were fixed in the models for baseline adjustment. ScO2 at baseline with oxygen supply shows an influence on long-term survival independent of age and sex (model 1) and independent of perioperative risks (estimated by EuroSCORE II) and hemoglobin (model 2). Valve prosthesis, in favor for balloon-expandable valves, is a predictor for 1 year survival (model 3)
an all-comer TAVI cohort? Second, is ScO₂ a valuable and independent predictor for long-term survival after TAVI?

We found a significant correlation of ScO₂ at baseline with markers for cardiovascular diseases. High-sensitive Troponin-T, NT-proBNP and EuroSCORE-II, a valid risk score estimating the 30 day mortality after cardiac surgery, correlated inversely and left-ventricular ejection function, serum hemoglobin concentration correlated positively with baseline ScO₂. In-depth insights about cerebral oxygen saturation and cardiovascular functionality have been described in the setting of cardiac arrest and low cardiac output. Coherent to our result, a study by Skhirtladze et al. reported an association of compromised left-ventricular pump function and diminished ScO₂ during threshold testing with concomitant induction of cardiac arrest in patients undergoing elective implantation of a cardioverter/defibrillator, a similar clinical setting to RVP or valve deployment during TAVI [18]. In detail, patients with LVEF < 30% exhibited the lowest ScO₂ values and had the highest incidence of critical cerebral desaturations, defined by the authors as > 20% drop from baseline or ScO₂ values < 50%.

A prospective study conducted by Robu et al. measured ScO₂ at baseline in 1616 patient undergoing cardiac interventions [19]. Baseline ScO₂ was observed to decrease with advanced age and was lower in women. Moreover, hemoglobin showed a significant association with ScO₂. Blood loss during surgery is known to reduce cerebral oxygen saturation; moreover, the correlation of serum hemoglobin concentration and ScO₂ is linear [6, 20, 21]. We also examined a strong correlation between hemoglobin and ScO₂. Furthermore, our mean ScO₂ at baseline was nearly identical to the baseline value reported by Robu et al. (60.0% in patients > 75 years vs. 60.4% in our cohort) [19]. One of the earlier and grand designed studies investigating ScO₂ and its correlation to baseline parameters was conducted by Heringlake et al. in 1178 patients scheduled for on-pump cardiac bypass surgery [22]. In line with our results, the authors found an inverse correlation of high-sensitive Troponin-T, NT-proBNP and EuroSCORE-II with ScO₂ at baseline. Since high-sensitive Troponin-T is not only a marker of myocardial injury, but comparable to NT-proBNP a measure of global cardiovascular dysfunction, ScO₂ is a valid parameter mirroring cardiovascular dysfunction in general [23, 24]. In an early invasive study by Paquet et al., mean baseline ScO₂ was the superior predictor for left-ventricular systolic dysfunction evaluated by transesophageal echocardiography compared to hemodynamic variables determined by pulmonary artery catheterization [25].

In addition, ScO₂ is known to correlate with mixed venous oxygen saturation in different clinical settings, an accepted surrogate parameter for the ratio between oxygen delivery and demand [3, 4]. This suggests that ScO₂ not only reflects the cerebral, but also the systemic oxygen balance. In summary, impaired cardiovascular and cardiopulmonary function is reflected by cerebral oxygen saturation.

Besides correlation of ScO₂ with baseline parameters for cardiovascular functionality, we describe impaired 1 year survival in patients with oxygen supply and ScO₂ < 56% at baseline. Moreover, ScO₂ at baseline under oxygen supply is a predictor for 1 year survival independent of age and sex and independent of overall perioperative risks estimated by EuroSCORE-II and hemoglobin. The predictive value of ScO₂ for survival has been described in different clinical settings.

A longitudinal study in patients with coronary artery disease demonstrated that a decline of ScO₂ during exercise corresponds with future adverse cardiac events and cardiac death throughout an observational period of 3–4 years [26]. In patients with cardiac arrest, higher ScO₂ levels at initiation of cardiopulmonary resuscitation (CPR) and during CPR were positive predictors for survival and reflect high-quality CPR [27]. A multicenter prospective study that included 504 out-of-hospital cardiac arrest victims who were still undergoing CPR on hospital arrival reported an association of higher cerebral oxygen saturations with return of spontaneous circulation and a perfect cut-off point for neurologically favorable survival to hospital discharge with ScO₂ > 50% under CPR [9].

In 2011, Heringlake et al. presented evidence that baseline cerebral oxygen saturation is an independent risk factor for 30 day and 1 year mortality in patients undergoing on-pump cardiac surgery [22]. But more important, failure of oxygen supplementation to increase ScO₂ beyond a cut-off value of 50% was a strong predictor for higher 30 day morbidity and mortality. In line with our cut-off value for 1 year survival at 56%, this emphasizes the potent diagnostic value of baseline ScO₂ monitoring to screen for non-oxygen responders and patient at risk for impaired mid- and long-term survival.

The concept of monitoring the brain as an index organ in patients with cardiovascular diseases is not novel [28]. Besides its value as prognostic marker, it remains an open question, whether monitoring or even optimizing ScO₂ during TAVI might improve the postoperative outcome and survival. So far, the best insights derived from randomized controlled trials in the setting of cardiac surgery with target therapies to optimize cerebral oxygen saturation. However, the results are conflicting: the results of a meta-analysis from 2017 did not support the hypotheses that cerebral NIRs-based algorithms have clinical benefits in cardiac surgery [29]; in contrast, a recent randomized controlled trial reported better memory outcome in the target therapy group but failing to improve morbidity and mortality endpoints [7]. In our study, a ScO₂ decline > 20% during the procedure was not associated with worse 1 year survival or prolonged in-hospital stay. Especially, patients with low
ScO2 at baseline not responding to oxygen supply have an impaired long-term outcome. In general, symptomatic severe aortic stenosis has a dismal prognosis, and valve intervention improves survival and quality of life significantly [30, 31]. Current guidelines strongly recommend early intervention in all patients [10, 32]. Therefore, omitting the intervention in case of low and non-responding ScO2 at baseline is not justifiable. ScO2 monitoring is a non-invasive and easy to implement diagnostic tool for preoperative risk assessment in patients scheduled for TAVI. We hypothesize that optimization of pretreatment is the key to improve results after TAVI.

Low ScO2 at baseline can be addressed by several strategies, e.g., by avoiding perioperative anemia and oxygen deficit. Furthermore, pretreatment of heart failure should be optimized and elective TAVI procedure should not be performed during acute decompensation and congestion. With this recent study, we could confirm the results of our previous pilot study, that patients with intraprocedural ScO2 decline of > 20% suffered more often from postoperative delirium [2]. For patients at high risk of developing a postoperative delirium, long and repetitive RVP as well as repetitive re-sheathing of a self-expandable valve should be avoided to reduce an intraprocedural ScO2 drop. Besides anatomical and morphological characteristics, the risk for intraprocedural cerebral desaturation should be considered to select the optimal valve system for each individual patient.

Our study has important limitations. We carried out a prospective single-center study with a heterogenous all-comer patient cohort. Although we have institutional ratified protocols for analgo-sedation during TAVI, individual sedation level is not comparable, but has an impact on cerebral oxygenation itself. Our results cannot be interpreted in the setting of anesthetized patients. Furthermore, ScO2 values measured in this study were generated by the Masimo oximeter and therefore not transferable to other oximetry systems.

**Conclusion**

Non-invasively measured cerebral oxygen saturation mirrors cardiovascular functionality. During TAVI, a baseline ScO2 <56% with oxygen supply is associated with reduced 1 year survival and ScO2 correlates inversely with prolonged in-hospital stay. Monitoring cerebral oxygen saturation by near-infrared spectroscopy is an easy diagnostic tool for screening patients with impaired outcome after TAVI.

**Acknowledgements** Philipp C. Seppelt was sponsored for medical conferences by Abbott, KelCon, Medos and Novartis. Silvia Mas-Peiro was supported by research grants by the Cardiopulmonary Institute (CPI) and the German Centre for Cardiovascular Research (DZHK). Kai Zacharowski declares that the results in this publication are thematically linked but not directly related to specific activities of the projects ENVISION and COVend, which have received funding from the European Union’s Horizon 2020 and Horizon Europe research and innovation programs, respectively, under Grant Agreement No 101015930 (ENVISION) and No 101045956 (COVend). Mariana Vasa-Nicotera is proctor for Abbott, Boston Scientific, Edwards Lifesience, and Medtronic.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Declarations**

**Conflict of interest** The other authors declare that they have no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Vahanian A, Beyersdorf F, Praz F et al (2021) 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg. https://doi.org/10.1093/EJCTS/EZAB389

2. Seppelt PC, Mas-Peiro S, de Rosa R et al (2020) Dynamics of cerebral oxygenation during rapid ventricular pacing and its impact on outcome in transfemoral transcatheter aortic valve implantation. Catheter Cardiovasc Interv 97(1):28795. https://doi.org/10.1002/ccd.28975

3. Paarmann H, Heringlake M, Sier H, Schön J (2010) The association of non-invasive cerebral and mixed venous oxygen saturation during cardiopulmonary resuscitation. Interact Cardiovasc Thorac Surg 11:371–373. https://doi.org/10.1510/icvts.2010.240929

4. Paarmann H, Heringlake M, Heinzle H et al (2012) Non-invasive cerebral oxygenation reflects mixed venous oxygen saturation during the varying hemodynamic conditions in patients undergoing transapical transcatheter aortic valve implantation. Interact Cardiovasc Thorac Surg 14:268–272. https://doi.org/10.1093/icvts/ivr102

5. Watzman HM, Kurth CD, Montenegro LM et al (2000) Arterial and venous contributions to near-infrared cerebral oximetry. Anesthesiology 93:947–953. https://doi.org/10.1097/00000542-200010000-00012

6. Suemori T, SHSBJASD (2017) Changes in cerebral oxygen saturation and haemoglobin concentration during paediatric cardiac surgery. Anaesth Intensive Care 45:220–227. https://doi.org/10.1177/0310057x1704050212

7. Uysal S, Lin H-M, Trinh M et al (2020) Optimizing cerebral oxygenation in cardiac surgery: a randomized controlled trial examining neurocognitive and perioperative outcomes. J Thorac Cardiovasc Surg 159:943-953.e3. https://doi.org/10.1016/J.JTCVS.2019.03.036
8. Skrifvars MB, Sekhon M, Äneman EA (2021) Monitoring and modifying brain oxygenation in patients at risk of hypoxic ischaemic brain injury after cardiac arrest. Crit Care 25:1–8. https://doi.org/10.1186/s13054-021-03678-3

9. Parnia S, Yang J, Nguyen R et al (2016) Cerebral oximetry during cardiac arrest. Crit Care Med 44:1663–1674. https://doi.org/10.1097/CCM.0000000000001723

10. Vahanian A, Barbados F, Praz F et al (2021) 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. https://doi.org/10.1093/eurheartj/ehab395

11. Mahoney FI, Barthel DW (1965) Functional evaluation: the Barthel index. Md State Med J 14:1

12. Mitchell AJ, Shukla D, Ajumal HA et al (2014) The mini-mental state examination as a diagnostic and screening test for delirium: systematic review and meta-analysis. Gen Hosp Psychiatry 36:627–633. https://doi.org/10.1016/j.genhosppsych.2014.09.003

13. Ely EW, Inouye SK, Bernard GR et al (2001) Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA 286:2703–2710

14. Koike A, Nagayama O, Hoshimoto-Iwamoto M et al (2008) Clinical significance of cerebral oxygenation during exercise in patients with peripheral arterial diseases of the European society of cardiology (ESC) and of the European society for vascular. Eur Heart J 39:763–816. https://doi.org/10.1093/eurheartj/ehx095

15. Généreux P, Piazza N, Alu MC et al (2021) Valve academic organization (ESO) the task force for the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS) document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European stroke organization (ESO) the task force for the diagnosis and treatment of peripheral arterial diseases of the European society of cardiology (ESC) and of the European society for vascular. Eur Heart J 39:763–816. https://doi.org/10.1093/eurheartj/ehx095

16. Heringlake M, Garbers C, Käbler JH et al (2011) Preoperative cerebral oxygen saturation and clinical outcomes in cardiac surgery. Circ Heart Fail. https://doi.org/10.1161/CIRCHEARTFAILURE.111.005931

17. Pang PS, Hermann GJ, Hunter BR et al (2019) TACIT (high sensitivity troponin t rules out acute cardiac insufficiency trial). Circ Heart Fail. https://doi.org/10.1161/CIRCHEARTFAILURE.119.005931

18. Skrifvars MB, Sekhon M, Äneman EA (2021) Monitoring and modifying brain oxygenation in patients at risk of hypoxic ischaemic brain injury after cardiac arrest. J Cardiothorac Vasc Anesth 34:3282–3289. https://doi.org/10.1097/JVA.0000000000001723

19. Popma JJ, Adams DH, Reardon MJ et al (2014) Transcatheter aortic valve replacement using a self-expanding bioprosthesis in high-risk patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 63:1972–1981. https://doi.org/10.1016/J.JACC.2014.02.556

20. Liu L, Qiang Z, Zhang J et al (2021) Effect of hemoglobin content on cerebral oxygen saturation during surgery for scoliosis in pediatric patients. BMC Anesthesiol 21(1):1–6. https://doi.org/10.1186/S12871-021-01382-X

21. Paquet C, Deschamps A, Denault AY, Couture P et al (2008) Balance regional cerebral oxygen saturation correlates with left ventricular systolic and diastolic function. J Cardiothorac Vasc Anesth 22:840–846. https://doi.org/10.1053/JJVCA.2008.02.013

22. Ibrahim AW, Trammell AR, Austin H et al (2015) Cerebral oximetry as a real-time monitoring tool to assess quality of in-hospital cardiopulmonary resuscitation and post cardiac arrest care. J Am Heart Assoc 4:e001859. https://doi.org/10.1161/JAHA.115.001859

23. Popma JJ, Adams DH, Reardon MJ et al (2014) Transcatheter aortic valve replacement using a self-expanding bioprosthesis in high-risk patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 63:1972–1981. https://doi.org/10.1016/J.JACC.2014.02.556
Authors and Affiliations

Philipp C. Seppelt\textsuperscript{1,2} \textbullet\textsuperscript{a} · Silvia Mas-Peiro\textsuperscript{1,2} · Arnaud Van Linden\textsuperscript{2,3} · Sonja Iken\textsuperscript{4} · Kai Zacharowski\textsuperscript{4} · Thomas Walther\textsuperscript{2,3} · Stephan Fichtlscherer\textsuperscript{1,2} · Mariuca Vasa-Nicotera\textsuperscript{1,2}

\textsuperscript{a} Philipp C. Seppelt
Philipp.Seppelt@kgu.de

\textsuperscript{1} Division of Cardiology, Department of Medicine III, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany

\textsuperscript{2} DZHK Partner Site Rhine-Main, German Centre for Cardiovascular Research, Berlin, Germany

\textsuperscript{3} Department of Cardiothoracic Surgery, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany

\textsuperscript{4} Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany